Star Therapeutics Announces $200M Private Financing To Support Its Pipeline Of Potential Best-in-Disease Therapies

The financing follows the July 2026 acquisition of Star subsidiary Vega Therapeutics and was co-led by OrbiMed and Janus Henderson Investors, with participation from Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Soleus Capital, and a leading sovereign wealth fund. Proceeds from the private financing will support Star’s next-generation pipeline of potential best-in-disease therapies, advancing its current preclinical programs into the clinic and expanding its pipeline with additional programs.

Across multiple companies, members of the Star team have invented four first-in-class therapies that are now in Phase 3 development or commercialized. The team has contributed to four successful acquisitions, including Vega Therapeutics, DICE Therapeutics, True North Therapeutics and iPierian. In July 2026, Incyte completed the acquisition of Star’s wholly owned subsidiary Vega Therapeutics in a transaction valued at up to $2 billion, which included Star’s lead program latarcibart (VGA039), a novel monoclonal antibody in Phase 3 development for von Willebrand disease. Additionally, in September 2026, Star’s spinout company Electra Therapeutics became a publicly traded company (NASDAQ:ETRA).